Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Dynamic contrast-enhanced MR evaluation of prostate cancer before and after endorectal high-intensity focused ultrasound.

Del Vescovo R, Pisanti F, Russo V, Battisti S, Cazzato RL, D'Agostino F, Giurazza F, Quattrocchi CC, Faiella E, Setola R, Giulianelli R, Grasso RF, Beomonte Zobel B.

Radiol Med. 2013 Aug;118(5):851-62. doi: 10.1007/s11547-012-0876-9. Epub 2012 Sep 17.

PMID:
22986696
2.

[MR detection of local prostate cancer recurrence after transrectal high-intensity focused US treatment: preliminary results].

Ben Cheikh A, Girouin N, Ryon-Taponnier P, Mège-Lechevallier F, Gelet A, Chapelon JY, Lyonnet D, Rouvière O.

J Radiol. 2008 May;89(5 Pt 1):571-7. French.

3.

Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection.

Perdonà S, Di Lorenzo G, Autorino R, Buonerba C, De Sio M, Setola SV, Fusco R, Ronza FM, Caraglia M, Ferro M, Petrillo A.

Urol Oncol. 2013 Aug;31(6):761-5. doi: 10.1016/j.urolonc.2011.07.010. Epub 2011 Sep 9.

PMID:
21906966
4.

Endorectal magnetic resonance imaging and magnetic resonance spectroscopy to monitor the prostate for residual disease or local cancer recurrence after transrectal high-intensity focused ultrasound.

Cirillo S, Petracchini M, D'Urso L, Dellamonica P, Illing R, Regge D, Muto G.

BJU Int. 2008 Aug;102(4):452-8. doi: 10.1111/j.1464-410X.2008.07633.x. Epub 2008 May 12.

5.

Role of magnetic resonance spectroscopic imaging ([¹H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA).

Panebianco V, Sciarra A, Ciccariello M, Lisi D, Bernardo S, Cattarino S, Gentile V, Passariello R.

Radiol Med. 2010 Dec;115(8):1314-29. doi: 10.1007/s11547-010-0575-3. Epub 2010 Sep 17. English, Italian.

PMID:
20852963
6.

[Accuracy of endorectal Magnetic Resonance Imaging (MRI) and Dynamic Contrast Enhanced-MRI (DCE-MRI) in the preoperative local staging of prostate cancer].

Baccos A, Schiavina R, Zukerman Z, Busato F, Gaudiano C, Salizzoni E, Fiorentino M, Golfieri R, Martorana G.

Urologia. 2012 Apr-Jun;79(2):116-22. doi: 10.5301/RU.2012.9207. Italian.

7.

Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease.

Punwani S, Emberton M, Walkden M, Sohaib A, Freeman A, Ahmed H, Allen C, Kirkham A.

Br J Radiol. 2012 Jun;85(1014):720-8. doi: 10.1259/bjr/61380797. Epub 2012 Jan 17.

8.

MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer.

Kim CK, Park BK, Lee HM, Kim SS, Kim E.

AJR Am J Roentgenol. 2008 May;190(5):1180-6. doi: 10.2214/AJR.07.2924.

PMID:
18430829
9.

Prostate cancer ablation with transrectal high-intensity focused ultrasound: assessment of tissue destruction with contrast-enhanced US.

Rouvière O, Glas L, Girouin N, Mège-Lechevallier F, Gelet A, Dantony E, Rabilloud M, Chapelon JY, Lyonnet D.

Radiology. 2011 May;259(2):583-91. doi: 10.1148/radiol.11101489. Epub 2011 Feb 25.

PMID:
21357522
10.

Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.

Vilanova JC, Barceló-Vidal C, Comet J, Boada M, Barceló J, Ferrer J, Albanell J.

AJR Am J Roentgenol. 2011 Jun;196(6):W715-22. doi: 10.2214/AJR.10.5700.

PMID:
21606259
12.

High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience.

Blana A, Walter B, Rogenhofer S, Wieland WF.

Urology. 2004 Feb;63(2):297-300. Review.

PMID:
14972475
13.

Detection of local recurrent prostate cancer after radical prostatectomy in terms of salvage radiotherapy using dynamic contrast enhanced-MRI without endorectal coil.

Rischke HC, Schäfer AO, Nestle U, Volegova-Neher N, Henne K, Benz MR, Schultze-Seemann W, Langer M, Grosu AL.

Radiat Oncol. 2012 Oct 31;7:185. doi: 10.1186/1748-717X-7-185.

14.

The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.

Somford DM, Hamoen EH, Fütterer JJ, van Basten JP, Hulsbergen-van de Kaa CA, Vreuls W, van Oort IM, Vergunst H, Kiemeney LA, Barentsz JO, Witjes JA.

J Urol. 2013 Nov;190(5):1728-34. doi: 10.1016/j.juro.2013.05.021. Epub 2013 May 13.

PMID:
23680307
15.

Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI.

Rouvière O, Girouin N, Glas L, Ben Cheikh A, Gelet A, Mège-Lechevallier F, Rabilloud M, Chapelon JY, Lyonnet D.

Eur Radiol. 2010 Jan;20(1):48-55. doi: 10.1007/s00330-009-1520-5. Epub 2009 Aug 19.

PMID:
19690866
16.

Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?

Schmuecking M, Boltze C, Geyer H, Salz H, Schilling B, Wendt TG, Kloetzer KH, Marx C.

Int J Radiat Biol. 2009 Sep;85(9):814-24. doi: 10.1080/09553000903090027.

PMID:
19701842
17.

Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy.

Roy C, Foudi F, Charton J, Jung M, Lang H, Saussine C, Jacqmin D.

AJR Am J Roentgenol. 2013 Apr;200(4):W361-8. doi: 10.2214/AJR.12.9106.

PMID:
23521479
18.

Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.

Casciani E, Polettini E, Bertini L, Emiliozzi P, Amini M, Pansadoro V, Gualdi GF.

Radiol Med. 2004 Nov-Dec;108(5-6):530-41. English, Italian.

PMID:
15722999
19.

Detection of Local Recurrence of Prostate Cancer After Radical Prostatectomy Using Endorectal Coil MRI at 3 T: Addition of DWI and Dynamic Contrast Enhancement to T2-Weighted MRI.

Kitajima K, Hartman RP, Froemming AT, Hagen CE, Takahashi N, Kawashima A.

AJR Am J Roentgenol. 2015 Oct;205(4):807-16. doi: 10.2214/AJR.14.14275.

PMID:
26397329

Supplemental Content

Support Center